Russia Aids Centre to Conduct HIV-VAC, Inc.'s Aids Vaccine Trials Business Wire
click here to return to Business Wire main menu
DonateNow





Russia Aids Centre to Conduct HIV-VAC, Inc.'s Aids Vaccine Trials

Business Wire - June 16, 1999


TORONTO--(BUSINESS WIRE)--June 16, 1999--HIV-VAC, Inc, (OTC BB:HIVC) has announced that Dr. Gordon Skinner, MD (Hons), DSc, FRCOG, FRCPath, the developer of HIV-VAC's AIDS vaccine, has reached an agreement with the Russia Aids Centre, who will conduct Phase I and Phase II trials of HIV-VAC's vaccine.

They will later proceed to the Phase III trial and product licensing. The vaccine was invented and has been under development by Dr. Skinner and his team for the past five years. Pre-clinical testing in small animals is nearing completion.

Dr. Skinner said that, "My work with Dr. Vadim Pokrovsky of the Russia Aids Centre arose from my previous association with Dr. I. Barinsky of Moscow's Ivanovsky Institute, who collaborated on the Skinner herpes simplex virus vaccine which has completed successful Phase III trials in the United States. The Russian side of the vaccine development program will be headed by Dr. Pokrovsky at the Russia Aids Centre, which has particular expertise in immune pathology and evaluation of efficacy and safety testing of vaccines. The HIV-VAC vaccine will be prepared and manufactured in collaboration with the Ivanovsky Institute, under the supervision of Dr. Skinner and the HIV-VAC's research team."

HIV-VAC's HIV vaccine was developed by Dr. Skinner at the University of Birmingham, United Kingdom. It has been under development for the last 10 years.

The HIV-VAC vaccine is expected to not only prevent the disease, and also may prevent the onset of AIDS in HIV-positive patients. Many scientists have been working on a vaccine for AIDS over the last 10 years. HIVC has developed a new approach to the AIDS problem through the creation of an intracellular vaccine based on technology proven in clinical trials with herpes genitalis and pre-clinical research into cytomegalovirus and equine herpes vaccines.

The HIV-VAC patented intracellular vaccine approach includes gp120/160 and uses core proteins p55, p24, p17 and others. The multi-protein approach used by HIV-VAC covers the whole spectrum of HIV virus proteins and is believed to offer a rational approach both as a vaccine and for therapeutic purposes. Because the HIV-VAC vaccine proteins are harvested from virus particles and from intracellular virus-coded proteins, the entire spectrum of virus proteins is available for presentation to the immune system.

The United Nations estimates that there are currently 30.6 million people infected worldwide with the AIDS virus. The disease is spreading at a rate of 10,000 people each day. It is estimated that the number of people infected with the AIDS virus by the end of the year 2000 will be 55 million.

The statements contained in this release which are not historical facts contain forward-looking information with respect to plans, projections or future performance of the company; the occurrence of which involves certain risks and uncertainties that could cause the company's actual results to differ materially from expected results. Such risks include the timing of implementation and the scope and success of the program described here.

For More Information: Phil Flynn, Investor Relations, 800-392-7961 For Live Interview: www.wallstreetinterview.com

--30--al/ny*

CONTACT: HIV-VAC, Inc. Phil Flynn, Investor Relations 800-392-7961
990616
BW990607


Copyright © 1999 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .